The Australian speciality pharma company Hatchtech Pty Ltd has recently announced a new round of funding to support ongoing DeOvo trials, as well as a new CEO.

An agreement dated 19 March 2012 has been made between Eden Research plc, an agrochemical and encapsulation technology company, and Phytalexin Ltd. This grants Phytalexin exclusive rights to Eden's formulations and encapsulation technologies for use in a head-lice product.

Foamix Ltd., the Israeli speciality pharma company, announced on 12 March 2012 that they had been granted a US patent for their PerFoam head lice treatment.

Omega Pharma have disclosed that the MBO by Couckinvest NV has succeeded in gaining over 99% of shares during the squeeze-out process.

Topaz Pharmaceuticals has been acquired by Sanofi-Pasteur, the vaccines unit of French pharmaceutical company Sanofi-Aventis, according to a report by the Philadelphia Business Journal published 3 February 2012.

Omega Pharma have confirmed that the takeover process initiated by Couckinvest NV now holds over 97% of shares.

The American Academy of Pediatrics was given an update on Natroba (spinosad) at its 2011 national conference and exhibition...

Fairy Tales Hair Care has sealed a US-wide distribution deal with SalonCentric for its Rosemary Repel® Lice Prevention System...

The US Food and Drug Administration (FDA) has accepted for filing a New Drug Application (NDA) from Topaz Pharmaceuticals...

The UK Advertising Standards Authority (ASA) has banned an internet promotion for a head lice repelling product...